Conestoga Capital Advisors LLC grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,911 shares of the company’s stock after purchasing an additional 2,560 shares during the period. Conestoga Capital Advisors LLC’s holdings in IDEXX Laboratories were worth $2,175,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the company. Advisors Capital Management LLC purchased a new position in IDEXX Laboratories in the 3rd quarter worth $262,000. Koch Industries Inc. raised its stake in IDEXX Laboratories by 44,533.1% in the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after acquiring an additional 1,396,113 shares during the last quarter. Zurich Insurance Group Ltd FI purchased a new position in IDEXX Laboratories in the 2nd quarter worth $2,651,000. Wells Fargo & Company MN raised its stake in IDEXX Laboratories by 7.8% in the 3rd quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock worth $52,706,000 after acquiring an additional 24,510 shares during the last quarter. Finally, Cabot Wealth Management Inc. purchased a new position in IDEXX Laboratories in the 3rd quarter worth $1,359,000. Hedge funds and other institutional investors own 86.63% of the company’s stock.
In other news, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $156.07, for a total transaction of $312,140.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total value of $8,171,280.00. Following the sale, the chairman now owns 1,064,573 shares in the company, valued at $161,091,186.36. The disclosure for this sale can be found here. Insiders have sold a total of 130,160 shares of company stock valued at $20,019,685 in the last quarter. Company insiders own 2.77% of the company’s stock.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.05. The business had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company’s revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the business posted $0.62 EPS. equities research analysts expect that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current fiscal year.
IDXX has been the subject of a number of research analyst reports. Canaccord Genuity restated a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research note on Friday, October 6th. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price for the company in a research note on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Finally, Piper Jaffray Companies initiated coverage on IDEXX Laboratories in a research note on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 target price for the company. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. IDEXX Laboratories presently has an average rating of “Buy” and a consensus price target of $177.43.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.